Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Shasun Chemicals and Drugs Limited
Shasun Chemicals and Drugs Limited
Activities:
Manufacturing
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
Bayer HealthCare and Johns Hopkins University to collaborate on new ophthalmic therapies
The partners will work jointly on the discovery and development of innovative drugs for the treatment of serious back-of-the-eye diseases
Berry Global invests to increase production capacity for healthcare products
Berry Global Group has invested in additional assets and manufacturing capabilities to increase its healthcare production capacity by up to 30% across three of its European sites
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Strides Shasun acquires three OTC brands from Moberg Pharma
Indian firm is building an over-the-counter drug franchise in regulated and emerging markets
Pharmaceutical
Indian generic manufacturers aim to enter the Japanese market
The penetration of generic drugs in Japan is a little more than 30% compared with more 80% in the US market
Ingredients
Indian API market on the up as domestic drug prices fall
Indian API manufacturers are branching out into new markets, while international suppliers could be hit by lower prices in the domestic market, writes Asia correspondent A Nair
Ingredients
Indian pharma exports to be hit by Falsified Medicines Directive
API exporters say latest EU move is a non-issue
Subscribe now